Developing a new treatment for opioid use disorder
Development of SBS-226, a MOR agonist / DOR antagonist, for OUD
This study is testing a new medication called SBS-226 to help people with opioid use disorder by providing pain relief without the same risk of addiction that comes with regular opioids.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sparian Biosciences, INC. NIH-funded |
| Lab location | 1 site (New York City, United States) |
| Project ID | NIH-10915840 on NIH RePORTER |
What this research studies
This research focuses on creating a new medication, SBS-226, which combines properties of a mu-opioid receptor agonist and a delta-opioid receptor antagonist to help treat opioid use disorder (OUD). The approach aims to provide effective pain relief while reducing the risk of addiction associated with traditional opioid medications. By investigating the effects of this new compound, the research seeks to improve treatment options for individuals struggling with OUD, particularly in the context of the ongoing opioid crisis exacerbated by the COVID-19 pandemic.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with opioid use disorder who may benefit from new treatment options.
Not a fit: Patients who are not struggling with opioid use disorder or those who do not require opioid medications for pain management may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a safer and more effective treatment for patients suffering from opioid use disorder.
How similar studies have performed: Previous research has shown promise in developing new treatments for opioid use disorder, but this specific approach with SBS-226 is novel.
Where this research is happening
New York City, United States
- Sparian Biosciences, INC. — New York City, United States (Active)
Researchers
- Principal investigator: Reich, Jeffrey — Sparian Biosciences, INC.
- Study coordinator: Reich, Jeffrey
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.